Tempus AI, Inc. - Class A (TEM)
TEM moved a median of -0.18% 30 minutes after news, and -0.22% by the close. How TEM actually reacts to news — the realized, point-in-time move the market made, measured across 935 labeled events over the last three years with zero look-ahead.
TEM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 50% | 926 |
| 30-min | -0.18% | 45% | 926 |
| 60-min | +0.06% | 52% | 926 |
| to close | -0.22% | 48% | 914 |
| Middle 50% of TEM reactions | -1.88% to +1.36% |
|---|---|
| Median reaction (30-min) | -0.18% |
| Measured reactions | 935 |
Half of all Tempus AI, Inc. - Class A news events land between -1.88% and +1.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TEM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | -0.40% | 43% | -0.60% |
| Analyst downgrades | 21 | +1.22% | 62% | +1.55% |
| Coverage initiations | 65 | +0.95% | 77% | -0.60% |
| Rating reiterations | 85 | -0.48% | 42% | -0.69% |
| Price-target raises | 21 | -0.47% | 48% | -2.06% |
| Price-target cuts | 15 | +0.19% | 67% | -0.18% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how TEM ranks against every other measured name →
That’s how TEM usually reacts — get an email when it moves on news →Email me when TEM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TEM's baseline. Nothing else.
Recent TEM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-4/A Tempus AI, Inc. | SEC filing · Form S-4 | SEC EDGAR | — | — | |
| Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 | Press release | Business Wire | -1.43% | -6.71% | |
| Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation | Press release | Business Wire | +0.60% | +1.81% | |
| Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model | Press release | Business Wire | -1.02% | -1.33% | |
| Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation | Press release | Business Wire | +0.83% | +0.17% | |
| Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology | Press release | Business Wire | -2.15% | -1.89% | |
| Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | Business Wire | -0.86% | -0.22% | |
| Form S-4 Tempus AI, Inc. | SEC filing · Form S-4 | SEC EDGAR | -1.17% | -5.00% | |
| Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs | Press release | Business Wire | -1.55% | -6.14% | |
| CellCarta Adds Tempus to CDx Commercialization Lab Network | Press release | PR Newswire | +1.15% | +2.04% | |
| Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications | Press release | Business Wire | +1.20% | +0.66% | |
| Form 10-Q Tempus AI, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.18% | -4.94% | |
| Form 8-K Tempus AI, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -6.18% | -4.94% | |
| Tempus Reports Second Quarter 2026 Results | Press release | Business Wire | -6.18% | -4.94% | |
| Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine | Press release | Business Wire | +0.19% | -2.83% | |
| Form 8-K Tempus AI, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | -2.44% | |
| Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform | Press release | Business Wire | -0.93% | -2.44% | |
| Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service | Press release | Business Wire | +0.26% | -5.92% | |
| Tempus to Report Second Quarter 2026 Financial Results on July 30 | Press release | Business Wire | +2.27% | +8.01% | |
| Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers | Press release | Business Wire | +4.22% | +4.33% | |
| Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm | Press release | Business Wire | -0.63% | +1.37% | |
| Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing | Press release | Business Wire | +1.20% | +0.12% | |
| Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | -2.27% | +2.60% | |
| Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members | Press release | Business Wire | -1.79% | -2.04% | |
| Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH | Press release | Business Wire | -0.31% | +6.88% | |
| Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development | Press release | Business Wire | -0.31% | +6.88% | |
| Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results | Press release | Business Wire | -0.31% | +6.88% | |
| Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community | Press release | Business Wire | -0.31% | +6.88% | |
| Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology | Press release | Business Wire | -2.82% | -5.36% | |
| Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio | Press release | Business Wire | -2.82% | -5.36% | |
| Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology | Press release | Business Wire | +1.72% | +9.31% | |
| Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows | Press release | Business Wire | -1.16% | +1.31% | |
| Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | Business Wire | -0.64% | -0.87% | |
| Form 8-K Tempus AI, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -0.87% | |
| Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use | Press release | Business Wire | -0.53% | +2.67% | |
| Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience | Press release | Business Wire | +2.07% | -0.87% | |
| Form 8-K Tempus AI, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | -1.03% | |
| Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution” | Press release | Business Wire | -2.57% | -1.94% | |
| Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes | Press release | Business Wire | -0.81% | +1.03% | |
| Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense | Press release | Business Wire | -2.22% | -7.10% | |
| Form 10-Q Tempus AI, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.31% | +5.27% | |
| Form 8-K Tempus AI, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -3.31% | +5.27% | |
| Tempus Reports First Quarter 2026 Results | Press release | Business Wire | -3.31% | +5.27% | |
| Tempus to Host Inaugural Investor Day on May 29, 2026 | Press release | Business Wire | -0.23% | -2.04% | |
| Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026 | Press release | Business Wire | -0.23% | -0.60% | |
| Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights | Press release | Business Wire | -0.80% | -1.66% | |
| Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine | Press release | Business Wire | -2.00% | -5.35% | |
| Tempus to Report First Quarter 2026 Financial Results on May 5 | Press release | Business Wire | -0.90% | -2.68% | |
| Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring | Press release | Business Wire | +1.69% | +12.04% | |
| Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026 | Press release | Business Wire | +3.01% | +3.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TEM section they belong to.
Where else TEM is measured.
TEM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Tempus AI, Inc. - Class A's median reaction calculated?
Every labeled TEM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 935 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of TEM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TEM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.